VERAXA Taps Oncology Veteran Dr. Rick Austin as CSO to Propel Cancer Therapies
Strategic Leadership for a New Era in Cancer Treatment VERAXA Biotech AG, an innovative Swiss company at the forefront of designing novel cancer therapies, today announced a significant enhancement to its leadership team with the appointment of Dr. Rick Austin as its new Chief Scientific Officer. The appointment, effective May 1st, 2025, comes as VERAXA…
